Emergent BioSolutions Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Emergent BioSolutions Inc. on August 15, 2008. The report details a material definitive agreement entered into by Emergent BioDefense Operations Lansing Inc., a wholly owned subsidiary of the registrant.
Key Financial Metrics
The filing does not provide specific values for revenue, profit, cash flow, margins, or total debt levels. The only financial metric disclosed relates to the interest rate on a specific credit facility:
- Interest Rate: One-month LIBOR index rate plus 2.0%.
Material Changes
On August 15, 2008, the subsidiary amended its Loan Agreement with Fifth Third Bank (originally dated June 11, 2007). The material changes include:
- Maturity Date Extension: The revolving line of credit maturity date was extended to June 1, 2009, subject to further extension by the bank.
- Letters of Credit: The amendment permits the issuance of letters of credit in addition to cash advances under the line of credit.
- Interest Terms: Interest accrues at an annual rate of one-month LIBOR plus 2.0%.
Except for these amendments, the original Loan Agreement remains in full force and effect.
Guidance, Outlook, and Risks
The filing does not contain management commentary, forward-looking guidance, or specific risk factors beyond the terms of the amended credit agreement. No unusual items or contingencies were disclosed in this report.
Investor Verification Checklist
- Verify the current outstanding balance on the Fifth Third Bank revolving line of credit.
- Confirm the current one-month LIBOR rate to calculate the effective interest cost.
- Review the subsidiary's liquidity position to assess the need for letters of credit versus cash advances.
- Check for any subsequent amendments or extensions to the June 1, 2009 maturity date.